ClinicalTrials.gg
WithdrawnNCT01452009Updated Feb 10, 2012

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

A Phase 3 interventional study of Travoprost Ophthalmic Solution, 0.004% (New Formulation) and TRAVATAN® in Open Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-10.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Management Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Glaucoma, Open-Angle by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Alcon.

Enrollment
109th of 112
0 · median 154
Started
2011
with 21 others
Phase 3
43 of 126
none open now
Registered
77th of 126
by date

Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 109th largest by enrollment of the 112 interventional ones that give a count, is one of 22 that started in 2011, is one of 43 in phase 3, and was the 77th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 126 studies in Glaucoma, Open-Angle by Alcon is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Glaucoma, Open-Angle by Alcon, or all of them as a file.
02

Study summary

A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • open angle glaucoma
  • ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age or older
  2. Either gender
  3. Any race/ethnicity
  4. Diagnosed with open-angle glaucoma (including patients with pseudoexfoliation and pigment dispersion) or ocular hypertension

Exclusion criteria

Exclusion Criteria:

  1. Patients with any form of glaucoma other than open-angle glaucoma.
  2. Patients with a central cornea thickness greater than 620 μm
  3. Patients with Shaffer angle Grade \< 2
  4. Patients with a cup/disc ratio greater than 0.80
  5. Patients with severe central visual field loss
  6. Best-Corrected Visual Acuity score worse than 55 ETDRS letters (20/80 Snellen equivalent)
  7. Chronic, recurrent or severe inflammatory eye disease
  8. or progressive retinal disease
  9. Other ocular pathology
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Travoprost Ophthalmic Solution, 0.004% (New Formulation)

    Drug: Travoprost Ophthalmic Solution, 0.004% (New Formulation)

  • Active comparator
    TRAVATAN®

    TRAVATAN® administered one drop once daily

    Drug: TRAVATAN®

Interventions

  • DrugTravoprost Ophthalmic Solution, 0.004% (New Formulation)

    Travoprost Ophthalmic Solution, 0.004% given one drop once daily

  • TRAVATAN® administered one drop once daily

06

What researchers measure

Primary outcomes

  1. Efficacy: mean IOP Efficacy as measured by mean IOP

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2011
First posted
Oct 14, 2011
Start
Nov 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Feb 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01452009
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Oct 14, 2011
Start date
Nov 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Feb 10, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion